Abreva and Zantac drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Abreva and Zantac. Common interactions include nephropathy among females and abdominal discomfort among males.

The phase IV clinical study analyzes what interactions people who take Abreva and Zantac have. It is created by eHealthMe based on reports of 40 people who take Abreva and Zantac from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.



On Nov, 17, 2022

40 people who take Abreva and Zantac together, and have interactions are studied.


What is Abreva?

Abreva has active ingredients of docosanol. It is often used in herpes labialis (oral herpes simplex). eHealthMe is studying from 16,320 Abreva users for its effectiveness, alternative drugs and more.

What is Zantac?

Zantac has active ingredients of ranitidine hydrochloride. It is often used in gastroesophageal reflux disease. eHealthMe is studying from 367,143 Zantac users for its effectiveness, alternative drugs and more.

Number of Abreva and Zantac reports submitted per year:

Abreva and Zantac drug interactions.

Common Abreva and Zantac drug interactions by gender *:

female:

  1. Nephropathy
  2. Oedema peripheral
  3. Osteoporosis
  4. Pneumonia
  5. Pyrexia
  6. Respiration
  7. Seizure
  8. Weight increased
  9. Agitation
  10. Anger

male:

  1. Abdominal discomfort
  2. Abdominal distension
  3. Diarrhoea
  4. Drug ineffective
  5. Dry eye
  6. Eating disorder
  7. Epistaxis
  8. Epstein-barr virus infection
  9. Fatigue
  10. Flatulence

Common Abreva and Zantac drug interactions by age *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

  1. Seizure

50-59:

  1. Blister
  2. Chills
  3. Constipation
  4. Contusion
  5. Diarrhoea
  6. Dizziness
  7. Drug hypersensitivity
  8. Dry skin
  9. Dysphagia
  10. Dysphoria

60+:

  1. Anaphylactic reaction
  2. Dyspnoea
  3. Asthenia
  4. Back pain
  5. Blister
  6. Chills
  7. Contusion
  8. Diarrhoea
  9. Drug intolerance
  10. Dysphagia

Common conditions people have *:

  1. Dizziness: 30 people, 75.00%
  2. Pain: 12 people, 30.00%
  3. Sleep Disorder: 2 people, 5.00%
  4. Primary Pulmonary Hypertension (primary high blood pressure that affects the arteries in the lungs and the right side of your heart): 2 people, 5.00%

* Approximation only. Some reports may have incomplete information.

Do you take Abreva and Zantac?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related studies

Alternative drugs to, pros and cons of the 2 drugs:

Browse all drug interactions of Abreva and Zantac:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Zantac interactions:

Browse all interactions between Zantac and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on docosanol and ranitidine hydrochloride (the active ingredients of Abreva and Zantac, respectively), and Abreva and Zantac (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study. Patients in the study may take other drugs besides Abreva and Zantac.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: